VANCOUVER, BC--(Marketwired - November 29, 2015) - biOasis Technologies Inc. (OTCQB: BIOAF) (TSX VENTURE: BTI) ("biOasis or the "Company), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier ("BBB"), announces the issuance of a US patent covering the delivery of therapeutic agents by using polypeptides from the company's Transcend BBB delivery vector. biOasis' Transcend Platform was originally based on the protein known as melanotransferrin (MTf or p97). Researchers at biOasis hypothesized that smaller sequences within the 80 kDa protein would bind to specific receptors for this protein thus initiating...
↧